BioSpace News Archive

BioMidwest

UCB presents latest data from generalized myasthenia gravis portfolio at 2023 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session

UCB announced that it will be presenting results from across its portfolio in generalized myasthenia gravis at the American Association of Neuromuscular & Electrodiagnostic Medicine annual meeting and the Myasthenia Gravis Association of America Scientific Session taking place November 1-4, 2023.

November 1, 2023
·
25 min read
South Rampart Pharma Expands Global Patent Portfolio with EU Approval for FDA Fast-Tracked SRP-001 for Pain

South Rampart Pharma, Inc. announced today the issuance of European Patent No. 3672938 by the European Patent Office (EPO) effective November 1, 2023.

November 1, 2023
·
5 min read
Business

REGENXBIO to Host Conference Call on November 8 to Discuss Third Quarter 2023 Financial Results and Recent Operational Highlights

REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, November 8, 2023, at 4:30 p.m. EST to discuss its financial results for the quarter ended September 30, 2023, and recent operational highlights.

November 1, 2023
·
1 min read
Biotech Beach

Diality to Unveil Moda-flx Hemodialysis System, Poster Data at ASN Kidney Week 2023

Diality Inc. today announced that it will introduce its Moda-flx Hemodialysis System™ at ASN Kidney Week 2023, Nov. 1-5 at the Pennsylvania Convention Center in Philadelphia.

November 1, 2023
·
1 min read
Biotech Bay

Bioluminescence Ventures Emerges from Stealth with $477M AUM

Bioluminescence Ventures today announced its emergence from stealth with $477M in assets under management across two funds: Bioluminescence Ventures Fund I, L.P., and Bioluminescence Ventures Fund II, L.P.

November 1, 2023
·
5 min read
Business

Precision BioSciences to Report Third Quarter Results on November 7, 2023

Precision BioSciences, Inc. today announced that it will publish financial results for the third quarter 2023 and provide a business update on November 7, 2023.

November 1, 2023
·
1 min read
Drug Development

Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease

Silence Therapeutics plc today announced positive topline results from the multiple dose component of the APOLLO phase 1 study of zerlasiran (formerly SLN360) in 36 adults with baseline lipoprotein(a), or Lp(a), levels at or over 150 nmol/L and stable atherosclerotic cardiovascular disease (ASCVD).

November 1, 2023
·
5 min read
Business

Calidi Biotherapeutics Announces Key Leadership Promotions and New Board Appointment

Calidi Biotherapeutics, Inc. today announced two key promotions from the clinical leadership team and the appointment of a new Board Director.

November 1, 2023
·
7 min read
Can-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track

Can-Fite BioPharma Ltd today confirmed that all of the Company’s clinical and business development activities are ongoing and proceeding by both its Israeli and US based staff.

November 1, 2023
·
6 min read
Antibe Completes First Clinical Study of Otenaproxesul’s New Formulation

Antibe Therapeutics Inc. is pleased to announce the completion of the pharmacokinetic/pharmacodynamic (“PK/PD”) study of otenaproxesul’s faster-absorbing formulation for acute pain.

November 1, 2023
·
3 min read